investor consid report singl factor make invest decis
total revenu million
trxade group inc headquart odessa fl provid supplier-to-pharmaci web-bas softwar platform enabl trade among healthcar buyer
seller pharmaceut accessori
maintain specul buy rate increas price target per share
per share due increas sector valuat sustain sale growth
trxade group inc opportun sustain revenu growth us commun pharmaci join
supplier-to-pharmaci web-bas softwar platform match buyer seller gener brand
drug march estim approxim pharmaci join web-bas platform
independ pharmaci estim nation commun pharmacist associ ncpa
ncpa estim purchas power independ pharmaci billion
sale come prescript drug estim trxd market share pharmaci platform could
approach revenu market share reach
anticip revenu growth support new pharmaci platform nearli ad per
month well increas accept exist custom drive transact growth
report march trxd report revenu growth million compani report
net incom per share compar loss continu oper million
per share project revenu million ep
maintain ep forecast per share revenu growth million
prior million compani ad least new commun pharmaci platform
total approxim
project net incom per share revenu growth million
compani ad new commun pharmaci platform total approxim
pleas view disclosur page
maintain specul buy rate trxade group inc rais price target
per share per share rate base annual growth revenu
million million growth forecast reflect compani expand number
commun pharmaci use trxade supplier-to-pharmaci web-bas softwar exchang platform least
march
price target per share impli share could appreci excess next
twelv month compani current trailing-twelv month forward price-to-sal multipl
prior respect accord msn money reuter averag trailing-twelv
month price-to-sal multipl internet content/inform pharmaceut distribut sector
prior appli multipl prior sale per share forecast
discount execut risk obtain year-ahead valu per share
trxade valuat like remain slight discount rel sector peer forecast revenu
million annual forecast period valuat improv like gradual conting
upon consist quarterli revenu growth expens leverag cash earn eventu sustain profit
forecast compani gener consist oper profit well gener cash
earn estim cash burn
due potenti period-to-period variabl transact execut compani supplier-to-
pharmaci web-bas softwar exchang platform well need new pharmaci approxim
per month engag platform believ share trxade suitabl primarili high-risk
trxade group inc headquart odessa florida own oper supplier-to-pharmaci web-bas
marketplac focus us pharmaceut industri compani core servic bring nation
independ pharmaci accredit nation supplier pharmaceut togeth provid effici
transpar buy sell opportun
compani design develop servic offer provid custom enhanc price transpar
purchas capabl valu ad servic singl platform order focu serv nation
approxim commun independ pharmaci us
predecessor compani trxade florida pharmacycl llc nevada limit liabil compani form
august serv web-bas market platform design enabl trade among healthcar buyer seller
pharmaceut accessori servic trxade nevada acquir trxade florida pursuant revers merger
result trxade florida becom wholli own subsidiari trxade nevada immedi follow
nevada-florida merger co-found compani collect own trxade nevada
decemb trxade nevada xcellink intern inc xcel enter definit merger
agreement provid merger trxade nevada xcel xcel surviv corpor
januari trxade becam publicli trade upon close merger compani one thousand-for-
one revers stock split merger revers stock split convers promissori note compani
view follow princip strateg platform enabl compani achiev mission
compani aim enhanc web-bas platform target community-bas retail pharmaci us
compani lead platform trxade exchang develop open widen distribut
channel retail commun pharmaci offer enabl custom view product manufactur
buy group wholesal real-tim continu basi order find lowest price exist
product given point time
follow-on platform trxade price predict model call rx guru integr product shortag
insight pharmaci acquisit benchmark order ascertain trend price varianc result
signific purchas opportun compani continu work new algorithm order upgrad
platform anticip futur price provid member custom opportun benefit real
price purchas opportun conceal rest industri
compani overal strategi web-bas exchang platform penetr exist independ retail
commun pharmaci well expand exist capabl clinic hospit government
compani sale depart continu add custom direct market custom
train program acceler growth trxd expand email market campaign emphas tool
provid competit price advantag list product shortag identif price trend part
compani market program involv educ new exist custom staff work close
new pharmaci first five transact trxade platform
basi forecast
forecast anticip compani ad approxim new commun pharmaci per month
supplier-to-pharmaci web-bas softwar platform march estim commun pharmaci
access supplier-to-pharmaci web-bas softwar exchang platform least state
revenu forecast base transact fee compani collect total valu transact
fee percentag higher gener drug transact brand drug transact anticip split
number gener brand drug transact compani charg contract
membership fee util supplier-to-pharmaci softwar platform
sinc compani focu switch web-bas softwar exchang platform model cost sale
zero anticip sg percentag revenu decreas
decemb compani tax loss carryforward nearli million
forecast includ compani pay tax
trade econom econom consult forecast firm project dispos person incom grow
annual rate trillion consum spend project reach nearli
billion billion increas base modest steadi econom growth
feder open market committe feder reserv board project gpd growth
compani abil grow base consum abil afford gener brand drug
backdrop increas dispos person incom buy sell drug supplier provid
trxade growth opportun
project revenu growth million prior million reflect approxim
new commun pharmaci join compani supplier-to-pharmaci web-bas softwar exchang platform
well increas number transact exist pharmaci increas util platform
project oper incom increas due higher revenu oper expens margin
improv anticip sg expens increas million support
growth commun pharmaci join compani supplier-to-pharmaci web-bas exchang platform
project oper margin vs revenu increas oper expens margin improv
non-oper expens forecast consist exclus interest expens increas
compar due higher averag debt balanc
project net incom per share prior
project revenu growth million reflect least new commun pharmaci
join compani supplier-to-pharmaci web-bas softwar exchang platform well increas number
transact exist pharmaci approxim enter increas util platform
project oper incom increas due higher revenu oper expens margin
improv forecast anticip sg expens increas
million support growth commun pharmaci join compani supplier-to-pharmaci web-bas exchang
platform project oper margin vs revenu increas oper expens
non-oper expens forecast consist exclus interest expens decreas
compar
project net incom per share
project cash earn increas work capit due primarili
increas receiv oper cover debt leas oblig project cash
increas decemb
project cash earn increas work capit due primarili increas
receiv prepaid asset oper cover repay debt leas
oblig increas cash decemb
nation commun pharmacist associ report place annual purchas power independ
commun pharmaci approxim billion sale come prescript drug one
import trend commun pharmaci market use technolog order find new innov
way increas product enhanc pharmaci effici reduc cost improv patient care facilit
commun health care provid patient independ pharmaci engag emerg
technolog opportun differenti competit
report indic independ commun pharmaci us decreas
averag independ commun pharmaci locat dispens prescript
per day decreas due primarili increas usag mail order consum
well consum util specialti medic prefer network commonli medicar part plan
pharmaci drug store
ibisworld observ pharmaci drug
store industri grown despit neg
side effect
regulatori environ
ibisworld predict industri revenu
billion estim billion
see chart right brand
prescript gener drug percentag hold
period revenu segment
combin grow annual reach
approxim billion industri
growth support increas
number insur individu due healthcar
reform peopl age medicar system
ibisworld anticip mani individu lower out-of-pocket cost prescript increas per
capita dispos incom enabl individu compliant prescript dosag
although growth project industri contend chang gener drug price reflect
reimburs rate accord survey nation commun pharmacist associ
pharmacist report spike gener drug acquisit price result reimburs rate lag
result industri receiv adjust reimburs rate previou prescript sale thu
ibisworld cite survey pharmaci benefit manag optumrx show gener drug account almost
two-third prescript fill across retail channel gener drug cost less
brand equival stimul volum growth gener drug
technolog improv effici within industri exampl technolog improv includ faster claim
transmiss central fill station central call center electron prescript transfer product databas well
incorpor new innov technolog latter benefit trxade pharmaci
incorpor technolog enabl purchas certain drug lower price
juli jone institut news report us drug shortag occur last five year
chronic drug shortag estim ad million annual us health-car cost
hospit doctor forc seek expens altern health-car worker must spend extra time
one reason drug shortag drug post fda current resolv drug shortag
discontinu list thinner profit margin especi older drug accord us govern
account offic shortag low cost medicin stem declin number supplier
certain product failur compani build enough product capac meet manufactur qualiti
pew charit trust intern societi engin conclud drug
shortag us result qualiti issu drug manufactur site includ manufactur activ
pharmaceut ingredi factor caus drug shortag includ market withdraw suppli chain
matur limit purchas manufactur incent limit market insight demand unclear regulatori
univers utah drug inform servic report number drug shortag us
march
revenu increas million million due higher fee incom web-bas platform
higher fee incom reflect mix pharmaceut sold platform brand versu gener drug
fee gener drug higher brand drug compani ad regist independ
pharmaci custom approxim primarili direct market custom train effort
project ep revenu million
oper expens consist exclus expens decreas million million due
primarili decreas employe cash compens compar year-ago period reflect lower staf
requir web-bas pharmaceut exchang platform becam oper expens includ
warrant option expens compar year-ago-period compani record
oper incom nearli compar loss million year-ago period improv
due higher revenu reduct oper expens oper margin expens decreas
non-oper expens decreas due primarili decreas debt convers
cost gain incom partli off-set increas interest expens
compani record loss discontinu oper compar loss million
discontinu oper gain sale discontinu oper net incom
per share compar loss continu oper million per share
revenu increas due higher fee incom web-bas platform
oper expens consist exclus expens decreas due primarili
decreas employe cash compens compar year-ago period compani record oper
incom compar loss improv due higher revenu
reduct oper expens oper margin expens decreas
non-oper incom compar expens due primarili gain
incom compar none year-ago period decreas interest expens
compani record loss discontinu oper compar loss
discontinu oper year-ago-period restat due sale decemb compani
equiti interest westminst llc wholli own subsidiari time
net incom break-even per share compar loss continu oper
break-even per share period compani record tax compani nearli million
tax loss carryforward decemb
cash earn off-set part increas work capit increas
work capit reflect reduct accrual payabl oper borrow
issuanc common stock cover repay debt increas cash decemb
compani total outstand debt decemb long-term portion includ
convert note matur may note payabl relat parti
short-term portion includ note payabl convert note relat parti
compani competit come three larg author distributor record adr distributor
well pharmaceut distributor buy group softwar
product compar trxade compani oper substanti greater financi manufactur
back resourc longer oper histori greater name recognit establish relationship
small privat compani provid pharmacy-to-pharmaci retail wholes overstock pharmaceut
includ rxcherrypick pharmsav genericbid bidrx pharmabid trxade attempt differenti
exchang provid pharmaci brand gener pharmaceut product
competit landscap includ buy group provid discount price member negoti
price one primari wholesal charg administr fee gener rang
compani also face competit compani like surecost provid inventori manag softwar
allow pharmaci compli primari supplier contract
given competit landscap pharmacy-to-pharmaci retail wholes trxade advantag marketplac
lie abil flexibl fast move adjust busi model address need custom
end trxade start revers auction model provid pharmaci prefer buy
format pharmacy-to-pharmaci trade capabl overstock pharmaceut
view princip risk underli stock
sinc januari trxade group inc rais approxim equiti capit addit equiti
capit compani issu debt fund oper compani issu debt total
respect decemb compani retain deficit million
anticip go concern issu prior year mitig compani abl achiev
profit forecast profit forecast depend upon abil execut busi plan
increas usag pharmaci web-bas pharmacy-to-pharmaci on-line marketplac
histor compani experienc recur oper loss compani like requir addit capit
acceler growth beyond annual forecast period compani commit
addit financ assur commit obtain equiti financ
dilut exist stockhold
state california florida nevada new mexico indiana enact law prohibit later movement
pharmaceut within distribut channel law prohibit wholesal sell pharmaceut
directli wholesal maintain inventori state may enact similar law place
restrict pharmaceut trade within trxade platform state law util feder
model pharmaci act allow addit chang rule restrict pharmacy-to-pharmaci trade
futur current law permit pharmaci trade annual inventori pharmaci
state law allow retail pharmaci abl trade product nation shortag statu
feder level implement track trace legisl pharmaceut pedigre
origin came implement stage end may restrict disrupt
movement pharmaceut along suppli chain cost compli new legisl could
burdensom smaller supplier
product distribut product liabil occur improperli manufactur product prove danger end
consum well product may becom adulter improp wareh method mode shipment
counterfeit product drug fake pedigre paper infiltr distribut channel could result
unintend liabil industri particip
compani must overcom pharmaci reluct adapt web-bas trade platform sinc
histor purchas pharmaceut internet neg connot neg includ
uncertainti respect origin puriti pharmaceut purchas trxade believ
brand custom base product offer develop custom embrac new marketplac concept
decemb trxade excess pharmaci pharmaceut wholesal supplier
custom decemb trxade approxim pharmaci pharmaceut wholesal
supplier custom compani lose buy group and/or wholesal result supplier
void would advers affect competit marketplac
offic director collect approxim outstand vote stock march offic
could potenti greatli influenc outcom matter requir stockhold approv decis may
may best interest sharehold
compani financi result equiti valu subject risk uncertainti includ competit
oper financi market regulatori risk and/or event risk may caus actual result differ
liquid potenti concern averag daili volum howev last three month end
march increas approxim share trade day trxd million share
outstand float approxim million investor awar thinli trade equiti could
thousand
compani report taglich brother estim
thousand
compani report taglich brother estim
thousand
sell gener administr
loss debt convers
loss incom continu oper
incom loss discontinu oper
net incom loss attribut inc
loss per share discontinu oper
sell gener administr
compani report taglich brother estim
thousand
compani report taglich brother estim
invest bank servic compani cover past month
